Dihexa: Uses, Benefits & Research

What is Dihexa?

Dihexa is a synthetic angiotensin IV analog (approximately 645 Da) designed to enhance cognitive function by targeting the AT4 receptor system. It is sometimes marketed as a potent nootropic, but this reputation rests entirely on animal research. Dihexa has never been tested in a completed human clinical trial for any indication.

The compound gained attention after in vitro assays showed it was orders of magnitude more potent than BDNF at inhibiting certain enzymes. This led to the widely repeated “10 million times more potent than BDNF” claim, which is based on enzyme inhibition assays in cell culture, not comparative human cognitive studies. Dihexa is classified as a research chemical with no regulatory approval anywhere in the world.

Mechanism of Action

Dihexa is proposed to work by binding to the AT4 receptor, also called IRAP (insulin-regulated aminopeptidase), which is involved in memory and cognitive function. In rodent studies, this binding enhances synaptic plasticity and activates the PI3K/AKT neuroprotection signaling pathway.

A key secondary mechanism involves the HGF/c-Met pathway, which promotes neurite outgrowth and synaptogenesis. This pathway is notable because HGF/c-Met is also a known pro-cancer signaling axis, raising unresolved safety concerns that were never addressed in the failed fosgonimeton clinical program.

All mechanistic understanding comes from rodent studies. No human binding studies, pharmacodynamic data, or target engagement biomarkers have been established.

Clinical Evidence

Human Studies

There are zero completed human clinical trials for Dihexa itself. The closest human data comes from fosgonimeton (ATH-1017), a clinical derivative developed by Athira Pharma.

The LIFT-AD Phase 3 trial (NCT05104424) tested fosgonimeton in 312 patients with mild-to-moderate Alzheimer’s disease. The trial failed to meet both primary and secondary endpoints in September 2024. Athira Pharma’s stock collapsed over 80% following the announcement, and the field has largely moved on from angiotensin IV-based cognitive enhancement.

Preclinical Evidence

Animal studies form the entire evidence base:

• McCoy 2013 (Mouse): Cognitive enhancement in Morris water maze
• Lee 2021 (APP/PS1 Mouse): PI3K/AKT pathway activation, amyloid reduction in Alzheimer’s model
• Biorxiv 2025 (Mouse): Working memory improvement in mild traumatic brain injury model

All findings are from rodent models. Species differences in AT4 receptor distribution and function significantly limit translation to humans.

Drug Interactions & Contraindications

No formal drug interaction studies have been conducted in humans. Theoretical interactions include additive effects with antihypertensives (angiotensin pathway involvement), unknown interactions with cognitive enhancers, and potential contraindication with cancer therapeutics due to c-Met pathway activation.

Dihexa is contraindicated in patients with active malignancy due to its activation of the HGF/c-Met pathway, which is a known oncogenic signaling axis. It should be avoided during pregnancy and breastfeeding.

Safety & Side Effects

No human safety data exists for Dihexa. The fosgonimeton (ATH-1017) Phase 3 trial reported adverse events, but since the trial failed efficacy endpoints, the safety profile was not established as sufficient for approval.

Theoretical safety concerns include oncogenic risk from HGF/c-Met pathway activation, cardiovascular effects from angiotensin pathway involvement, and unknown CNS effects due to complete absence of human data. No established human dosing, pharmacokinetics, or pharmacodynamic characterization exists.

Honest Bottom Line

Dihexa represents one of the most inflated claims in the peptide space with essentially zero human evidence. The “10 million times more potent than BDNF” claim comes from in vitro enzyme assays, not human cognitive studies. The only clinical trial data for a related compound — fosgonimeton in the LIFT-AD trial — failed in 2024. There are no human safety data, no established dosing, no PK/PD characterization, and no clear path to FDA approval. The HGF/c-Met pathway activation raises unresolved oncogenic safety concerns. This is purely a research chemical.